- Location
therapeutic areas
"-
Forest Laboratories Has Entered Into a Definitive Agreement to Acquire Aptalis
Jan 9, 2014Forest Laboratories, Inc. (NYSE:FRX) today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis company, for $2.9 billion in cash from ...
Tags: Forest Laboratories, definitive agreement, acquisition, Aptalis
-
TransCelerate Is Launching Three New Global Initiatives to Further Advance Efficiency
Nov 12, 2013US-based TransCelerate BioPharma is launching three new global initiatives to further advance efficiency in clinical trials and accelerate the development of new medicines: creation of common clinical trial protocol templates, development ...
Tags: TransCelerate, clinical trial, Global Initiative, Cubist Pharmaceuticals
-
Iroko Pharmaceuticals Has Received The FDA Approval to Market ZORVOLEX Capsules
Oct 23, 2013US-based iCeutica announced that its partner Iroko Pharmaceuticals has received the US Food and Drug Administration (FDA) approval to market ZORVOLEX (diclofenac) capsules, a non-steroidal anti-inflammatory drug (NSAID) that utilizes ...
-
X-Chem and AstraZeneca Have an Drug Collaboration That Covers Astrazeneca's Areas
Oct 8, 2013US-based biotechnology company X-Chem and UK-based pharmaceutical company AstraZeneca have entered into an expanded global drug discovery collaboration that covers all of AstraZeneca’s therapeutic areas and multiple target classes. ...
Tags: Drug, pharmaceutical
-
Multiplexed Single Molecule Immunoassay Was Launched by Quanterix
Sep 18, 2013US-based Quanterix has launched multiplexed single molecule immunoassay technology for improving diagnosis and potential treatment of complex diseases. The multiplexed single molecule immunoassays study, which was partly funded by the ...
-
KARO Has Achieved Its First Milestone in a Research Agreement with Pfizer
Sep 9, 2013Swedish biotechnology firm Karo Bio (KARO) has achieved its first milestone in a research agreement with Pfizer for the development of drugs for treatment of autoimmune diseases. The achievement of milestone in the RORgamma project ...
-
TPI Has Signed a Multi-Million Dollar Joint Investment Framework Agreement with BioMotiv
Aug 15, 2013Specialty life-science investment company Torrey Pines Investment (TPI) has signed a multi-million dollar joint investment framework agreement with BioMotiv, a biotech accelerator associated with The Harrington Project for Discovery & ...
Tags: Drug Development, Torrey Pines
-
KU Leuven and FIT Biotech Reached a Global License and Partnership Agreement
Aug 2, 2013KU Leuven and FIT Biotech have reached a global license and partnership agreement for the development of novel immunotherapeutics leveraging FIT Biotech's gene transport unit (GTU) technology for transient in vivo expression of monoclonal ...
-
Pfizer Is Planning for Internal Classification of Its Commercial Operations
Jul 31, 2013Pfizer is planning for internal classification of its commercial operations into three business segments, which will include developed and emerging markets, in an effort to deliver value to consumers and patients. The three business ...
Tags: Pfizer, Commercial Businesses
-
Health Ministry Inspect That FDI Limit Is Not at The Cost of The Public Health Goals
Jul 16, 2013India’s Health ministry is planning to organize an inter-ministerial meeting to inspect that the current foreign direct investment (FDI) limit in the pharma industry is not at the cost of the public health goals. The Department of ...
-
Chinese Have Been Using The Green and Leafy Andrographis Paniculata to Treat Inflammation
Jul 9, 2013Chinese have been using the green and leafy andrographis paniculata to treat inflammation, fever and pain for decades, with its cultivation dating back to at least the 1950s in the southern province of Guangdong. The plant, better known ...
Tags: Chinese Medicine, Medicine
-
Dr. Michael A. Eldon Will Present a Webinar Focuses on Pk/Pd Modeling and Simulation
May 13, 2013San Carlos, California, United States of America (Free-Press-Release.com) May 7, 2013 -- Rosa & Co. LLC today announced that Dr. Michael A. Eldon, Principal Scientific Fellow, VP, Clinical Pharmacology, Nektar Therapeutics, will present a ...
-
Rosa & Co. LLC Announced Physiomap and Physiopd Collaboration Results
May 13, 2013FOR IMMEDIATE RELEASE San Carlos, California, United States of America (Free-Press-Release.com) May 9, 2013 -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that ...
Tags: Construction, Decoration
-
Liquidia Technologies Is Planning to Set up a New Ophthalmology-Focused Company
May 6, 2013Liquidia Technologies is planning to set up a new ophthalmology-focused company to manufacture products that address the unmet needs, growth therapeutic areas and to maximize the return for its investors. The proposal follows the success ...
Tags: Liquidia, Ophthalmology Company
-
Pfizer Has Decided to Discontinue The Development of Filibuvir
Mar 13, 2013Biopharmaceutical company Pfizer has decided to discontinue the development of filibuvir, an experimental hepatitis C drug, following a strategic review and capital allocation. The drug, which is in mid-stage clinical testing, is facing ...
Tags: Pfizer, filibuvir drug, drug
